Anis Hamid

1.9k total citations
54 papers, 599 citations indexed

About

Anis Hamid is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Anis Hamid has authored 54 papers receiving a total of 599 indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Pulmonary and Respiratory Medicine, 26 papers in Oncology and 20 papers in Cancer Research. Recurrent topics in Anis Hamid's work include Prostate Cancer Treatment and Research (36 papers), Cancer Immunotherapy and Biomarkers (14 papers) and Cancer, Lipids, and Metabolism (11 papers). Anis Hamid is often cited by papers focused on Prostate Cancer Treatment and Research (36 papers), Cancer Immunotherapy and Biomarkers (14 papers) and Cancer, Lipids, and Metabolism (11 papers). Anis Hamid collaborates with scholars based in United States, Australia and United Kingdom. Anis Hamid's co-authors include Christopher J. Sweeney, Kathryn P. Gray, Carolyn Evan, Massimo Loda, Grace Shaw, Atish D. Choudhury, Eliezer M. Van Allen, Niall M. Corcoran, Brandon Bernard and Laura E. MacConaill and has published in prestigious journals such as Journal of Clinical Oncology, Nature Protocols and Annals of Oncology.

In The Last Decade

Anis Hamid

48 papers receiving 597 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anis Hamid United States	13	425	206	182	166	94	54	599
Alan D. Smith United Kingdom	14	361 0.8×	236 1.1×	171 0.9×	234 1.4×	68 0.7×	35	635
Carolyn Evan United States	10	387 0.9×	187 0.9×	168 0.9×	140 0.8×	78 0.8×	20	527
Davide Bimbatti Italy	13	398 0.9×	205 1.0×	158 0.9×	173 1.0×	75 0.8×	56	560
Yusuke Imamura Japan	15	399 0.9×	154 0.7×	169 0.9×	315 1.9×	61 0.6×	77	765
Nicholas I. Simon United States	11	521 1.2×	154 0.7×	253 1.4×	240 1.4×	75 0.8×	31	720
Bruce Keith United States	10	262 0.6×	243 1.2×	105 0.6×	121 0.7×	86 0.9×	15	504
Toshiaki Shinojima Japan	15	290 0.7×	196 1.0×	180 1.0×	273 1.6×	32 0.3×	46	664
Ione Tamagnini Italy	13	249 0.6×	325 1.6×	141 0.8×	269 1.6×	51 0.5×	24	720
Jaymes Holland United States	14	299 0.7×	259 1.3×	143 0.8×	294 1.8×	43 0.5×	25	769
P. Neven Belgium	14	192 0.5×	531 2.6×	222 1.2×	184 1.1×	129 1.4×	24	836

Countries citing papers authored by Anis Hamid

Since Specialization

Citations

This map shows the geographic impact of Anis Hamid's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anis Hamid with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anis Hamid more than expected).

Fields of papers citing papers by Anis Hamid

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anis Hamid. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anis Hamid. The network helps show where Anis Hamid may publish in the future.

Co-authorship network of co-authors of Anis Hamid

This figure shows the co-authorship network connecting the top 25 collaborators of Anis Hamid. A scholar is included among the top collaborators of Anis Hamid based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anis Hamid. Anis Hamid is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sandhu, Simran, Megan Crumbaker, Joanna Chan, et al.. (2025). 2391P LuPARP: Phase I trial of [177Lu]Lu-PSMA-617 (LuPSMA) and olaparib in patients (pts) with metastatic castration resistant prostate cancer (mCRPC). Annals of Oncology. 36. S1216–S1217.

Tolmeijer, Sofie H., Emily Kwan, Anthony M. Joshua, et al.. (2024). 1616P Circulating tumour DNA (ctDNA) measurements and PET-imaging to evaluate response in a phase Ib trial of metastatic castration-resistant prostate cancer (mCRPC) treated with Lutetium-177-PSMA-617 (LuPSMA) plus pembrolizumab (PRINCE). Annals of Oncology. 35. S975–S976. 1 indexed citations

Hamid, Anis, Jihye Park, Saud H. AlDubayan, et al.. (2024). Whole exome correlates in metastatic hormone sensitive prostate cancer (mHSPC): Results from E3805 CHAARTED.. Journal of Clinical Oncology. 42(16_suppl). 5088–5088.

Hofman, Michael S., Ramin Alipour, Sidney M. Levy, et al.. (2024). 1608P Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial. Annals of Oncology. 35. S970–S970. 2 indexed citations

Richardson, Gary, Raed Moh’d Taiseer Al-Rajabi, Dipesh Uprety, et al.. (2023). A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors. Cancers. 15(9). 2553–2553. 2 indexed citations

Hamid, Anis, Shivakumar Keerthikumar, Anupama Pasam, et al.. (2023). Circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with olaparib plus ¹⁷⁷lutetium-prostate specific membrane antigen-617 (¹⁷⁷Lu-PSMA-617) in the LuPARP trial.. Journal of Clinical Oncology. 41(16_suppl). 5064–5064.

Hamid, Anis, Emily Grist, Gerhardt Attard, et al.. (2023). Landscape and impact of germline pathogenic variants (PVs) in metastatic hormone sensitive prostate cancer (mHSPC): Ancillary study of E3805 CHAARTED.. Journal of Clinical Oncology. 41(16_suppl). 5082–5082. 1 indexed citations

Bernard, Brandon, Philippe Barthélémy, Marianne Paesmans, et al.. (2021). Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer. Prostate Cancer and Prostatic Diseases. 25(2). 199–207. 7 indexed citations

Barthélémy, Philippe, Spyridon Sideris, Sandrine Rorive, et al.. (2021). 624P Prevalence and clinical impact of PTEN status in patients (pts) with de novo metastatic hormone sensitive prostate cancer (mHSPC). Annals of Oncology. 32. S661–S661.

10.

Hamid, Anis, Hsin-Chieh Huang, Yu‐Hui Chen, et al.. (2021). Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial. Annals of Oncology. 32(9). 1157–1166. 39 indexed citations

11.

Richardson, Gary, Francis Parnis, Anis Hamid, et al.. (2021). 137P Phase I dose-finding study of a novel anti-CTLA-4 antibody ADG116 as monotherapy in patients with advanced solid tumors. Annals of Oncology. 32. S1436–S1437. 1 indexed citations

12.

Ravi, Praful, Grace Shaw, Sarah C. Markt, et al.. (2020). 792P A retrospective review of the survival outcomes of patients with nonseminomatous germ cell tumors (NSGCTs) with and without teratoma in the primary. Annals of Oncology. 31. S603–S603.

13.

Hamid, Anis & Atish D. Choudhury. (2019). Biological and therapeutic advances in the pursuit of effective immunotherapy for prostate cancer. Current Opinion in Urology. 30(1). 30–35. 6 indexed citations

14.

Hamid, Anis, et al.. (2018). Communicating prognosis of patients with advanced cancer between health care providers: a tertiary cancer center review of written correspondence. Annals of Palliative Medicine. 7(4). 404–410. 4 indexed citations

15.

Hamid, Anis, Kathryn P. Gray, Ying Huang, et al.. (2018). Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy. European Urology Oncology. 2(5). 475–482. 19 indexed citations

16.

Hamid, Anis, Michael J. Morris, & Ian D. Davis. (2018). Clinical Trials of Metastatic Castration-sensitive Prostate Cancer: Recent Progress and New Horizons. European Urology Focus. 5(2). 165–167. 2 indexed citations

17.

Hamid, Anis, Sarah C. Markt, Cécile Vicier, et al.. (2018). Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era. Clinical Genitourinary Cancer. 17(1). 58–64.e1. 6 indexed citations

18.

Hamid, Anis & Christopher J. Sweeney. (2017). A new standard-of-care for advanced-stage disease. Nature Reviews Clinical Oncology. 14(10). 592–593. 3 indexed citations

19.

Hamid, Anis, et al.. (2017). The Inhibitory Effect of Lemon Juice (Citrus limon) on Vibrio parahaemolyticus in Raw Oyster (Crassostrea virginica). 2(2). 31–31. 1 indexed citations

20.

Ha, F., Andrew Grigg, Joe McKendrick, et al.. (2016). Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era. Annals of Hematology. 95(5). 809–816. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact